Vytronus, Inc., a privately held medical device company developing novel technologies for the treatment of cardiac arrhythmias, announced today that its early feasibility study of automated ultrasound technology for the treatment of persistent atrial fibrillation...
Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to evaluate KidneyIntelX™ across over 3,500 patients...
Top-line Data Readout on Target for early Q4 2019 Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today...
GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced...
The results of a randomized clinical trial conducted in the United Kingdom indicate that gentamicin is not a suitable alternative for ceftriaxone as part of first-line treatment for gonorrhea. But gentamicin combined with azithromycin might be appropriate for treating...
The costs and timelines to conduct clinical trials continue to increase, along with study complexity. While much of the focus within clinical trials has been on improving data integrity and overall study efficiency, addressing costs, timeline and complexity issues,...
Email
Text